Response to Letter to Editor

Response to letter to editor for: “Lycopodium clavatum for the management of urolithiasis: A randomised double blind placebo controlled trial”

Dear Researcher,

We are glad to receive your experiences on the use of Lycopodium clavatum and urolithiasis. This empirical and traditional medicine has been used in Homoeopathy with multifactorial action on various diseases. Regarding the article titled ‘Lycopodium clavatum for the management of urolithiasis: A randomised double blind placebo controlled trial’, we would like to share with you that we could not find the efficacy of Lycopodium in urolithiasis in double-blinded randomised trial, but a positive trend was seen in pain relief.

However, it is to apprise you that in previous studies conducted by the Central Council for Research in Homoeopathy titled ‘To Explore the utility of Homoeopathic Medicine Lycopodium clavatum in Urinary Calculi’[1] and ‘A Multicentre Observational Study to Ascertain the Role of Homoeopathic Therapy in Urolithiasis’, [2] we found Homoeopathy medicine Lycopodium clavatum as effective in the dissolution of stones.

In India, the effect of Lycopodium clavatum has also been explored in preclinical studies as anticancer[3,4] and hepatoprotective[5,6] medicine. Its pharmacological action in the dissolution of renal stones needs to be further evaluated in future research. We appreciate your efforts in this direction.

We look forward to more exchange of knowledge in the future.

Praveen Oberoi, Pritha Mehra*

*Address for correspondence: Dr. Pritha Mehra, Research Officer (H), Dr. D. P. Rastogi Central Research Institute of Homoeopathy, A 1/1, Sector 24, Noida. E-mail: drpritha@gmail.com

Received: 09.12.2019; Accepted: 09.12.2019; Published: 27.12.2019.

References


This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.